FoundationOne genomic tests for advanced solid tumors and FoundationOne Heme genomic tests for rare cancers, leukemia, and cancers for which standard of care therapies have been exhausted. This coverage is provided only when these diagnostic tests are recommended by a member's health care provider and furnished by the Foundation Medicine cancer care provider.